A composition containing a culture supernatant of dental pulp-derived stem cells, adipose-derived stem cells, umbilical cord-derived stem cells or immortalized stem cells thereof in which the composition contains angiotensin-converting enzyme 2 (ACE2) and is used for administration to a healthy person or a healthy animal for preventing infection of the healthy person or the healthy animal with a virus that uses ACE2 as a receptor can be used as a medicine for preventing infection with a virus that uses ACE2 as a receptor, such as COVID-19, or the like when administered to a healthy person or a healthy animal.

A composition containing a culture supernatant of dental pulp-derived stem cells, adipose-derived stem cells, umbilical cord-derived stem cells or immortalized stem cells thereof in which the composition contains angiotensin-converting enzyme 2 (ACE2) and is used for administration to a healthy person or a healthy animal for preventing infection of the healthy person or the healthy animal with a virus that uses ACE2 as a receptor can be used as a medicine for preventing infection with a virus that uses ACE2 as a receptor, such as COVID-19, or the like when administered to a healthy person or a healthy animal.

Disclosed are enhanced umbilical cord-derived adhesive stem cells, a preparation method therefor, and a use thereof. The enhanced umbilical cord-derived adhesive stem cells have an anti-inflammatory effect, a blood vessel regeneration effect, or a nerve regeneration effect, thereby being usable in a pharmaceutical composition or a cell therapeutic agent for treating or preventing various diseases.

Disclosed are enhanced umbilical cord-derived adhesive stem cells, a preparation method therefor, and a use thereof. The enhanced umbilical cord-derived adhesive stem cells have an anti-inflammatory effect, a blood vessel regeneration effect, or a nerve regeneration effect, thereby being usable in a pharmaceutical composition or a cell therapeutic agent for treating or preventing various diseases.

A method for a therapeutic compound from a plurality of birth tissues for the treatment of at least breathing and inflammation ailments. The method includes receiving a plurality of birth tissues from a mammalian donner. Each received birth tissue is processes to provide a refined material. This refined material is evaluated to determine at least a concentrate of at least one constituent. Portions of the processed birth tissues are then mixed to provide an initial blend of materials having a predetermined ration of the constituents to provide the therapeutic compound.

A method for a therapeutic compound from a plurality of birth tissues for the treatment of at least breathing and inflammation ailments. The method includes receiving a plurality of birth tissues from a mammalian donner. Each received birth tissue is processes to provide a refined material. This refined material is evaluated to determine at least a concentrate of at least one constituent. Portions of the processed birth tissues are then mixed to provide an initial blend of materials having a predetermined ration of the constituents to provide the therapeutic compound.

A method for a therapeutic compound from a plurality of birth tissues for the treatment of at least breathing and inflammation ailments. The method includes receiving a plurality of birth tissues from a mammalian donner. Each received birth tissue is processes to provide a refined material. This refined material is evaluated to determine at least a concentrate of at least one constituent. Portions of the processed birth tissues are then mixed to provide an initial blend of materials having a predetermined ration of the constituents to provide the therapeutic compound.

The present disclosure provides methods for treating hematologic malignancies in a recipient subject in need thereof comprising administering to the recipient subject an effective amount of donor myeloid progenitor cells, and an effective amount of donor umbilical cord blood (UCB) cells, wherein the UCB cells and the myeloid progenitor cells are HLA matched. In some embodiments, the donor for the myeloid progenitor cells is not related to the recipient subject and/or the donor for the UCB cells. Also disclosed herein are methods for promoting early myeloid recovery in a recipient subject following UCB transplantation.

The present disclosure provides methods for treating hematologic malignancies in a recipient subject in need thereof comprising administering to the recipient subject an effective amount of donor myeloid progenitor cells, and an effective amount of donor umbilical cord blood (UCB) cells, wherein the UCB cells and the myeloid progenitor cells are HLA matched. In some embodiments, the donor for the myeloid progenitor cells is not related to the recipient subject and/or the donor for the UCB cells. Also disclosed herein are methods for promoting early myeloid recovery in a recipient subject following UCB transplantation.

The present invention relates to a method of treating acute or chronic systemic graft-versus-host disease (GVHD) with extracellular vesicles, e.g., exosomes obtained from human cardiospheres or cardiosphere-derived cells (CDCs), wherein systemic GVHD involves, e.g., at least two organs selected from the group consisting of the skin, mucosa, gastrointestinal tract, liver, lungs, joints and fascia, genitalia, and eyes. The present invention also provides a pharmaceutical formulation comprising extracellular vesicles, e.g., exosomes obtained from human cardiospheres or CDCs, for systemic administration, e.g., intravenous infusion, to a human subject in need of treatment of systemic GVHD.